Roche’s Genentech Doubles Investment in North Carolina Biomanufacturing Hub to $2 Billion

Holly Springs, North Carolina | Jan 20 (GeokHub) Genentech, the U.S. biotechnology unit of Swiss pharmaceutical giant Roche, has announced plans to more than double its investment in a biomanufacturing facility in North Carolina, lifting total spending on the project to approximately $2 billion.

The expanded facility, located in Holly Springs, is expected to become operational by 2029 and will focus on producing next-generation therapies for metabolic diseases, including treatments targeting obesity and related conditions.

Jobs and Manufacturing Scale-Up

Genentech said the increased investment will support over 2,000 jobs, comprising around 500 high-wage manufacturing roles and 1,500 construction positions during the build-out phase. The expansion is designed to significantly increase production volumes and strengthen the company’s large-scale manufacturing capabilities in the United States.

The move builds on an earlier commitment made in May 2025, when Genentech invested more than $700 million in the North Carolina site as part of a broader strategy to deepen its U.S. footprint.

Part of a Broader U.S. Push

The North Carolina expansion fits into Roche’s wider plan to invest $50 billion in the United States, reflecting growing industry momentum to localize pharmaceutical manufacturing. That trend has been reinforced by policy pressure from the U.S. government encouraging drugmakers to onshore production and reduce reliance on overseas supply chains.

By scaling up domestic biomanufacturing, Genentech aims to improve supply resilience, accelerate innovation, and support the growing demand for advanced metabolic treatments.